Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
CID-16020046 (CI-16020046) is a novel, potent and selective GPR55 (LPI receptor) antagonist / inverse agonist which can block GPR55-mediated endothelial wound healing and reverse LPI-inhibited platelet aggregation. It suppresses the constitutive activity of GPR55 with IC50 of 0.15 uM. GPR55 is a G protein-coupled receptor that, at nM concentrations, is weakly activated by certain compounds. This lysophosphatidylinositol (LPI) receptor is also responsive to some cannabinoids; it is called G protein-coupled receptor 55 (GPR55). Due in large part to the lack of selective GPR55 antagonists, the function of GPR55 remains unclear despite its involvement in a number of (patho)physiologic processes.
ln Vitro |
CID16020046 inhibited agonist-induced receptor activation in yeast cells expressing human GPR55. The compound exhibited antagonistic effects on extracellular signal-regulated kinases activation and LPI-mediated Ca2+ release in human embryonic kidney (HEK293) cells that were stable in their expression of human GPR55. CID16020046 reduced the activation of serum response element, nuclear factor κ of activated B cells (NF-κB), nuclear factor of activated T cells (NFAT), and lysophosphatidylinositol (LPI) in a concentration-dependent manner. It also prevented GPR55 internalization and the translocation of NFAT and NF-κB.
|
---|---|
ln Vivo |
CID16020046 decreases proinflammatory cytokines and ameliorates intestinal inflammation in model organisms. In healthy mice, CID16020046 has no effect on locomotor activity or anxiety levels[1].
|
Cell Assay |
After being reconstituted in 500 μL PBS, 2 × 106 cells were preincubated with 1, 5, and 10 μM CID16020046 or DMSO for 30 minutes. The cells were then stimulated for an additional half-hour at 37°C using 1 nM of monocyte chemotactic protein 1 (MCP-1). Fifteen minutes prior to the incubation period's conclusion, Alexa Fluor 647 anti-mouse CD11b was added. Cells were counted on an FACSCalibur flow cytometer following the addition of the fixative solution. Data were reported as a percentage change to the vehicle treatment, and experiments were run in triplicate.
|
References |
Molecular Formula |
C25H19N3O4
|
---|---|
Molecular Weight |
425.436065912247
|
Exact Mass |
425.14
|
Elemental Analysis |
C, 70.58; H, 4.50; N, 9.88; O, 15.04
|
CAS # |
834903-43-4
|
Appearance |
Solid powder
|
SMILES |
CC1=CC=C(C=C1)C2=NNC3=C2C(N(C3=O)C4=CC=C(C=C4)C(=O)O)C5=CC(=CC=C5)O
|
InChi Key |
VGUQVYZXABOXCX-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C25H19N3O4/c1-14-5-7-15(8-6-14)21-20-22(27-26-21)24(30)28(18-11-9-16(10-12-18)25(31)32)23(20)17-3-2-4-19(29)13-17/h2-13,23,29H,1H3,(H,26,27)(H,31,32)
|
Chemical Name |
4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-c]pyrazol-5-yl]benzoic acid
|
Synonyms |
CID-16020046; CID16020046; CID 16020046
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~100 mg/mL (~235.1 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (58.76 mM) in 20%PEG300 80% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (5.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3505 mL | 11.7525 mL | 23.5051 mL | |
5 mM | 0.4701 mL | 2.3505 mL | 4.7010 mL | |
10 mM | 0.2351 mL | 1.1753 mL | 2.3505 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.